Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01148420
Other study ID # 13530-01
Secondary ID
Status Completed
Phase Phase 4
First received June 21, 2010
Last updated February 12, 2014
Start date January 2009
Est. completion date July 2012

Study information

Verified date February 2014
Source Women's Health Care Clinic, Torrance, California
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effectiveness and acceptability of high dose MPA (20mg oral 3 times a day) for 3 days combined with an injection of DMPA 150 mg intramuscularly in the treatment of acute heavy, prolonged uterine bleeding who have been identified as being eligible for outpatient management


Description:

Excessive vaginal bleeding is a frequent problem for reproductive age women and accounts for many office and emergency room visits. This bleeding is caused by cancer, endocrinologic problems, liver failure, benign tumors of the uterus, and cervix, as well as hormone imbalances, such as anovulatory cycling.

Even though excessive vaginal bleeding is very common, there has been very little research into ways to manage it. For non-pregnant women who have stable vital signs and are not hemorrhaging or experiencing severe anemia, outpatient therapy is generally attempted. Textbooks recommend treatment with high dose oral contraceptives pills (one tablet orally 2 times a day for 5 days). Recently, Munro et al published a small study using high doses of oral progestin (MPA 20mg 3 times daily for 7 days then one daily for 21 days). The median time to bleeding cessation was 3 days. Munro reported having difficulty enrolling adequate numbers of patients to achieve the statistical significance.

The investigators propose a pilot project to study clinical responses to a new hormonal therapy the blends the high dose oral therapy with the longer acting injectable progestin. The pilot clinical trial is designed to study 50 women who are bleeding and whose treatment is amenable to outpatient therapy. Routine care will be provided to each of the women before she is approached for study enrollment.

This study, therefore, is designed to provide short term proven therapy of 20 mg MPA tablets 3 times a day for 3 days combined with the injectable progestin (DMPA) that lasts for 3 months.

Patients will be called within 24 hours and 48 hours following their first study visit to ascertain their bleeding status and their use of medication, as well as any significant side effects they may be experiencing. Patients will be asked to return to the clinic on day 3 for a repeat hemoglobin and interval history. Those women who are still having any bleeding on day 3 will be contacted on day 5.

The primary outcome measures of the part of the study will be the time elapsed to slowing acute bleeding as well as compliance with study medications. The patient's time to complete cessation of bleeding and percent of women having complete bleeding cessation will also be calculated. Results of the biopsies done before randomization will also be evaluated to see if they had any influence on study outcomes. From the degree of responses seen in this pilot study, a larger clinical trial may be designed.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date July 2012
Est. primary completion date October 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Age 18- 50

- Non-pregnant

- Candidate for outpatient management

- Able to understand and follow instructions

- Vital signs stable

- No severe anemia

- No medical conditions requiring transfusion

Exclusion Criteria:

- Pregnancy

- Breast cancer current or in last 5 years

- Allergy to MPA or DMPA

- Previous hormonal therapies

- Unstable vital signs

- Bleeding excessive enough to require surgical therapy or hospital admission

- Desire for pregnancy in next 6 months

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Medroxyprogesterone 17-Acetate
Medroxyprogesterone 20mg orally 3 times a day for 3 days
medroxyprogesterone acetate
Depo Provera 150mg Intramuscular injection

Locations

Country Name City State
United States Harbor-UCLA Urgent Care Torrance California

Sponsors (1)

Lead Sponsor Collaborator
Women's Health Care Clinic, Torrance, California

Country where clinical trial is conducted

United States, 

References & Publications (3)

Munro MG, Mainor N, Basu R, Brisinger M, Barreda L. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2006 Oct;108(4):924-9. — View Citation

Munro MG, New Concepts in nongestational acute uterine bleeding.Contemporary Ob-GYN;53(1):52-57

Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility, 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005

Outcome

Type Measure Description Time frame Safety issue
Primary Cessation of Bleeding Within 5 Days Patients were called within 24 hours and 48 hours following their first study visit to ascertain their bleeding status and their use of medication, as well as any significant side effects they msy have been experiencing. Patients were asked to return to the clinic on day 3 for a repeat hemoglobin and interval history. Those women who were still having any bleeding on day 3 were contacted on day 5 3-5 days Yes
Secondary Patient Perception of the Acceptability of the Treatment Results from a survey question that assessed the subjects' satisfaction with the therapy on a scale of 1-3. 1 = poor; 2 = good; 3 = excellent. End of the trial; up to day 5 No
Secondary Satisfaction and Willingness to Recommend Treatment Participants were asked whether they would recommend this treatment to a friend End of the trial; up to day 5 No
See also
  Status Clinical Trial Phase
Completed NCT04528108 - Chinese Medicine Periodic Therapy for Dysfunctional Uterine Bleeding During Adolescence With Yin Deficiency and Blood Heat Syndrome Phase 2
Completed NCT04428684 - COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg Phase 1
Recruiting NCT00549159 - CavatermTM vs TCRE in Women With DUB Phase 4
Not yet recruiting NCT04579965 - Misotac vs Combined Oral Contraceptive Pill in the Treatment of Symptomatic Isthmocele N/A
Terminated NCT01581905 - Study of Conventional Laparoscopic Hysterectomy Versus Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution N/A
Completed NCT02326922 - The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding Phase 1/Phase 2
Recruiting NCT04396483 - Dysfunctional Uterine Bleeding After Tubal Sterilization N/A
Completed NCT01628432 - Effect of Salpingectomy During Conservative Hysterectomy N/A
Terminated NCT01776203 - Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist Phase 4
Completed NCT01173965 - Endometrial Ablation With Non-hysteroscopic Methods Phase 4
Active, not recruiting NCT02103764 - Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB Phase 3
Not yet recruiting NCT04290013 - Effects of Tranexemic Acid Versus Norethisterone Acetate on Endometrial Vasculature . Phase 3